Table IV.

Voriconazole Pediatric Dose Number for Various Pediatric Subpopulations

Dose formula	Neonates (0–1 months)	Infant (1–24 months)	Children (2–12 years)	Adolescents (12–16 years)
Young’s Rulea, b	0.0511	0.608	1.48	1.25
Clark’s Rulea, c	0.866	1.17	1.36	1.74
Modified Weight Rulea, d	1.18	1.59	1.85	2.37
Body surface areaa, e	2.05	2.05	2.05	2.05
FDA-approved labeled dosef	Not indicated	Not indicated	Not indicated	2.33

Age was taken to be the mid-point of the subpopulation age (i.e., 0.5 months, 12.5 months, 7 years, and 14 years for neonates, infants, children, and adolescents, respectively). Conversion from dose to dose number employed a BSA-derived volume of 34.7, 67.4, 127.6, and 220.3 ml for neonates, infants, children, and adolescents, respectively. BSA employed height and weight, which were taken to be the 50 percentile boy value in the CDC growth charts for 0.5 months, 12.5 months, 7 years, and 14 years for neonates, infants, children, and adolescents, respectively (17,18). Drug solubility was taken to be 0.39 mg/ml (14)

^aIn calculating pediatric dose for each subpopulation and from each dose formula, the adult dose was taken to be 200 mg

^bYoung’s Rule employs age, which was taken to be the mid-point of the subpopulation age (i.e., 0.5 months, 12.5 months, 7 years, and 14 years for neonates, infants, children, and adolescents, respectively). From Young’s Rule, the dose was calculated to be 0.692, 16.0, 73.7, and 107.7 mg for neonates, infants, children, and adolescents, respectively

^cClark’s Rule employs weight, which was taken to be the 50 percentile boy weight in the CDC growth charts for neonates, infants, children, and adolescents (17,18). From Clark’s Rule, the dose was calculated to be 11.7, 30.7, 67.5, and 149 mg for neonates, infants, children, and adolescents, respectively

^dModified Weight Rule employs weight, which was taken to be the 50 percentile boy weight in the CDC growth charts for neonates, infants, children, and adolescents (17,18). From Modified Weight Rule, the dose was calculated to be 16.0, 41.8, 92.0, and 204 mg for neonates, infants, children, and adolescents, respectively

^eBody surface area employs height and weight, which were taken to be the 50 percentile boy value in the CDC growth charts for neonates, infants, children, and adolescents (17,18). From body surface area, the dose was calculated to be 27.8, 35.9, 102, and 176 mg for neonates, infants, children, and adolescents, respectively

^fThe FDA-approved labeled dose for candidiasis from the package insert is 200 mg for the pediatric population > 12 years old (27)